Who Buys Fluoxetine from India — 522 Importers Behind a $235.3M Market
India's fluoxetine import market is served by 522 active buyers who collectively imported $235.3M across 3,702 shipments. AVET PHARMACEUTICALS INC C/O (UNITED STATES) leads with a 48.0% market share, followed by ACCORD HEALTHCARE INC, and BROWN AND BURK LIMITED. The top 5 buyers together control 70.4% of total import value, reflecting a concentrated buyer landscape.
Top Fluoxetine Importers — Ranked by Import Value
AVET PHARMACEUTICALS INC C/O (UNITED STATES) is the leading fluoxetine importer from India, holding a 48.0% share of the $235.3M market across 3,702 shipments from 522 buyers. The top 5 buyers — AVET PHARMACEUTICALS INC C/O (UNITED STATES), ACCORD HEALTHCARE INC, (CANADA), BROWN AND BURK LIMITED (UNITED KINGDOM), IMRES B.V. (NETHERLANDS), TORRENT PHARMA INC, (UNITED STATES) — collectively control 70.4% of total import value.
Top Fluoxetine Buyers & Importers
Ranked by import value · 522 active buyers · Indian Customs (DGFT) data
| # | Buyer & Formulations | Value | Suppliers | Share |
|---|---|---|---|---|
| 1 | AVET PHARMACEUTICALS INC C/OUNITED STATES FLUOXETINE TABLETS USP 10 MGFLUOXETINE TABLETS USP 20 MGFLUOXETINE CAPSULES 20MG | $112.8M | 5 | 48.0% |
| 2 | ACCORD HEALTHCARE INC,CANADA PH.DRU.& MED.: FLUOXETINE CAPSULES BP 20PH.DRU.& MED.: ACH FLUOXETINE 20MG CAPSU | $25.4M | 5 | 10.8% |
| 3 | BROWN AND BURK LIMITEDUNITED KINGDOM FLUOXETINE 20MG CAPSULES - TAX IFLUOXETINE BP 20MG CAPSULESFLUOXETINE BP 20 MG CAPSULES | $10.6M | 5 | 4.5% |
| 4 | IMRES B.V.NETHERLANDS FLUOXETINE CAPSULES USP 20 MG -PHARMA DRUG&MED:FLUOXETINE ACCORD 20MG EFLUOXETINE CAPSULES USP 20 MG 10X10'SX1 | $8.8M | 5 | 3.7% |
| 5 | TORRENT PHARMA INC,UNITED STATES FLUOXETINE TABLETS USP 10 MGFLUOXETINE TABLETS USP 20 MGFLUOXETINE CAPSULES 20MG | $7.9M | 5 | 3.4% |
| 6 | ORION CORPORATION,FINLAND FLUOXETINE CAPSULES 20MG(FLUOXETINE ORIOFLUOXETINE CAPSULES 20MG100'SNOSFLUOXETINE CAPSULES 20MG (FLUOXETINE ORI | $3.3M | 5 | 1.4% |
| 7 | ACCORD HEALTHCARE INC.,CANADA PH.DRU.& MED.: FLUOXETINE CAPSULES BP 20PH.DRU.& MED.: ACH FLUOXETINE 20MG CAPSU | $2.7M | 5 | 1.2% |
| 8 | TIME-CAP LABS,UNITED STATES FLUOXETINE TABLETS USP 10 MGFLUOXETINE TABLETS USP 20 MGFLUOXETINE CAPSULES 20MG | $2.7M | 5 | 1.1% |
| 9 | J. KNIPPER & COMPANYUNITED STATES FLUOXETINE TABLETS USP 10 MGFLUOXETINE TABLETS USP 20 MGFLUOXETINE CAPSULES 20MG | $2.6M | 5 | 1.1% |
| 10 | DR. REDDYS LABORATORIES, INCUNITED STATES FLUOXETINE TABLETS USP 10 MGFLUOXETINE TABLETS USP 20 MGFLUOXETINE APOTEX 20MG CAPSULES | $2.6M | 5 | 1.1% |
| 11 | MEDREICH PLCUNITED KINGDOM FLUOXETINE 20MG CAPSULES - TAX IFLUOXETINE BP 20MG CAPSULESFLUOXETINE BP 20 MG CAPSULES | $2.2M | 5 | 0.9% |
| 12 | APL SWIFT SERVICES (MALTA) LTD.,MALTA FLUOXETINE CAPSULES 20MG(FLUOXETINE AUROFLUOXETINE CAPSULES 20MG(FLUOXETINA AUROFLUOXETINE CAPSULES 20MG98'S | $2.1M | 5 | 0.9% |
| 13 | DR REDDYS LABORATORIES INCUNITED STATES FLUOXETINE 20MG CAPSULES - TAX IFLUOXETINE TABLETS USP 10 MGFLUOXETINE TABLETS USP 20 MG | $1.9M | 5 | 0.8% |
| 14 | APOTEX PTY LTDAUSTRALIA FLUOXETINE APOTEX 20MG CAPSULESFLUOXETINE APOTEX 20MG CAPSULES 2X14SFLUOTEX - TAX INVOICE NO: 701208970 DT: 24.06.2024283569PCS | $1.9M | 5 | 0.8% |
| 15 | AUROBINDO PHARMA USA INCUNITED STATES FLUOXETINE TABLETS USP 10 MGFLUOXETINE TABLETS USP 20 MGFLUOXETINE CAPSULES 20MG | $1.5M | 5 | 0.6% |
Related Analysis
Market Analysis: Top Importing Countries & Importers
Comprehensive geographic market intelligence dashboard
Which companies are buying Fluoxetine — and from which countries?
Flow of Fluoxetine exports from India: each country's share and the named importers behind the numbers
Fluoxetine — Buyer Countries to Key Importers
Trade flow: top importing countries → named buyer companies
Market Analysis: Top Importing Countries & Their Importers
1United States
United States emerges as the first largest importing country, achieving a total trade value of $154.4M through 389 shipments. This represents a market share of 65.6% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: United States has a diverse importer base, with their top importers including:
• AVET PHARMACEUTICALS INC C/O - $112.8M (73.1% of country's total business)
• TORRENT PHARMA INC, - $7.9M (5.1% of country's total business)
• TIME-CAP LABS, - $2.7M (1.7% of country's total business)
• J. KNIPPER & COMPANY - $2.6M (1.7% of country's total business)
• DR. REDDYS LABORATORIES, INC - $2.6M (1.7% of country's total business)
• Rest of United States's importers - $25.9M (16.8% of country's total business)
Key Insight: United States demonstrates strong market positioning with an average shipment value of $397.0K, indicating premium pricing strategy compared to the market average of $63.6K.
United States is a key market for Fluoxetine imports, representing 65.6% of total trade value.
2Canada
Canada emerges as the second largest importing country, achieving a total trade value of $30.3M through 16 shipments. This represents a market share of 12.9% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Canada has a diverse importer base, with their top importers including:
• ACCORD HEALTHCARE INC, - $25.4M (83.7% of country's total business)
• ACCORD HEALTHCARE INC., - $2.7M (9.1% of country's total business)
Key Insight: Canada demonstrates strong market positioning with an average shipment value of $1.9M, indicating premium pricing strategy compared to the market average of $63.6K.
Canada is a key market for Fluoxetine imports, representing 12.9% of total trade value.
3United Kingdom
United Kingdom emerges as the third largest importing country, achieving a total trade value of $19.2M through 137 shipments. This represents a market share of 8.1% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: United Kingdom has a diverse importer base, with their top importers including:
• BROWN AND BURK LIMITED - $10.6M (55.2% of country's total business)
• MEDREICH PLC - $2.2M (11.4% of country's total business)
Key Insight: United Kingdom demonstrates strong market positioning with an average shipment value of $140.0K, indicating premium pricing strategy compared to the market average of $63.6K.
United Kingdom is a key market for Fluoxetine imports, representing 8.1% of total trade value.
4Netherlands
Netherlands emerges as the fourth largest importing country, achieving a total trade value of $9.3M through 7 shipments. This represents a market share of 3.9% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Netherlands has a diverse importer base, with their top importers including:
• IMRES B.V. - $8.8M (95.2% of country's total business)
Key Insight: Netherlands demonstrates strong market positioning with an average shipment value of $1.3M, indicating premium pricing strategy compared to the market average of $63.6K.
Netherlands is a key market for Fluoxetine imports, representing 3.9% of total trade value.
5South Africa
South Africa emerges as the fifth largest importing country, achieving a total trade value of $3.8M through 0 shipments. This represents a market share of 1.6% of the total market activity, demonstrating their significant presence in the industry.
Key Insight: South Africa demonstrates strong market positioning with an average shipment value of $3.8M, indicating premium pricing strategy compared to the market average of $63.6K.
South Africa is a key market for Fluoxetine imports, representing 1.6% of total trade value.
Buyer Segment Analysis
TransData Nexus Fluoxetine buyer market intelligence
1Buyer Segment Analysis
The 522 buyers of Fluoxetine imported from India can be categorized into several segments:
1. Pharmaceutical Companies: Entities like AVET Pharmaceuticals Inc. (USA, $112.82M), Accord Healthcare Inc. (Canada, $25.40M), and Dr. Reddy's Laboratories, Inc. (USA, $2.56M) are pharmaceutical manufacturers that import Fluoxetine for formulation and distribution. Their purchasing patterns typically involve large, consistent orders to meet production demands.
2. Distributors: Companies such as Brown and Burk Limited (UK, $10.59M) and Imres B.V. (Netherlands, $8.81M) act as intermediaries, supplying Fluoxetine to various healthcare providers. They often place regular orders based on market demand forecasts.
3. Contract Manufacturers: Entities like Torrent Pharma Inc. (USA, $7.94M) and Time-Cap Labs (USA, $2.66M) import Fluoxetine to manufacture products on behalf of other companies. Their procurement is project-based, aligning with contractual obligations.
4. Re-exporters: Companies such as Orion Corporation (Finland, $3.32M) may import Fluoxetine for re-export to other markets, leveraging trade agreements and logistical advantages. Their buying behavior is influenced by global market demands and regulatory environments.
Country-Specific Import Regulations
TransData Nexus Fluoxetine buyer market intelligence
1Country-Specific Import Regulations
For the top five importing countries, the import regulations for Fluoxetine (HS Code: 30049099) are as follows:
1. United States
2. Canada
3. United Kingdom
4. Netherlands
5. South Africa
Demand Drivers & Market Opportunity
TransData Nexus Fluoxetine buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Fluoxetine in importing countries is driven by several factors:
1. Disease Prevalence: Fluoxetine is primarily used to treat major depressive disorder, anxiety disorders, and certain eating disorders. According to the World Health Organization (WHO), depression affects over 264 million people globally as of 2020, indicating a substantial patient base for Fluoxetine.
2. Government Healthcare Programs: Many countries have national healthcare programs that subsidize or cover the cost of essential medicines, including Fluoxetine. For instance, the UK's National Health Service (NHS) provides Fluoxetine as part of its formulary, ensuring widespread access.
3. Universal Health Coverage Expansion: Countries expanding their universal health coverage, such as South Africa's National Health Insurance (NHI) initiative, are increasing access to essential medicines, thereby boosting demand for Fluoxetine.
4. WHO Essential Medicines List Procurement: Fluoxetine is listed on the WHO Model List of Essential Medicines, prompting many countries to include it in their national essential medicines lists and procurement programs.
5. Tender-Based Purchasing: Government and international organizations often procure medicines through tenders to ensure cost-effectiveness and supply security. The presence of 522 buyers across 101 countries, as per TransData Nexus data, indicates a competitive market where tender-based purchasing is prevalent.
These factors collectively contribute to the sustained and growing demand for Fluoxetine in the global market.
Common Questions — Fluoxetine Buyers & Importers
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
QWho is the largest fluoxetine buyer importing from India?
Based on import volume and value, AVET PHARMACEUTICALS INC C/O (UNITED STATES) leads with $112.8M in imports and a 48.0% market share — the highest of any single fluoxetine importer. ACCORD HEALTHCARE INC, (CANADA) and BROWN AND BURK LIMITED (UNITED KINGDOM) are the next largest buyers.
QHow many companies buy fluoxetine from India?
There are 522 active fluoxetine buyers importing from India, with a combined market of $235.3M across 3,702 shipments to 101 countries. The top 5 buyers hold 70.4% of total import value, while the remaining 517 buyers handle the other 29.6%.
QWhich countries import the most fluoxetine from India?
The top importing countries for fluoxetine from India are United States (65.6%), Canada (12.9%), United Kingdom (8.1%), Netherlands (3.9%), South Africa (1.6%). These markets represent the largest demand centres for Indian pharmaceutical exports of fluoxetine, with buyers ranging from government procurement agencies to private pharmaceutical distributors.
QWhat is the average import order value for fluoxetine from India?
The average import transaction value for fluoxetine from India is $63.6K, with an average unit price of $18.42 per unit. Order sizes vary significantly based on buyer type — government tenders tend to be larger while private distributors place more frequent smaller orders.
Buyer Segment Analysis
TransData Nexus Fluoxetine buyer market intelligence
1Buyer Segment Analysis
The 522 buyers of Fluoxetine imported from India can be categorized into several segments:
1. Pharmaceutical Companies: Entities like AVET Pharmaceuticals Inc. (USA, $112.82M), Accord Healthcare Inc. (Canada, $25.40M), and Dr. Reddy's Laboratories, Inc. (USA, $2.56M) are pharmaceutical manufacturers that import Fluoxetine for formulation and distribution. Their purchasing patterns typically involve large, consistent orders to meet production demands.
2. Distributors: Companies such as Brown and Burk Limited (UK, $10.59M) and Imres B.V. (Netherlands, $8.81M) act as intermediaries, supplying Fluoxetine to various healthcare providers. They often place regular orders based on market demand forecasts.
3. Contract Manufacturers: Entities like Torrent Pharma Inc. (USA, $7.94M) and Time-Cap Labs (USA, $2.66M) import Fluoxetine to manufacture products on behalf of other companies. Their procurement is project-based, aligning with contractual obligations.
4. Re-exporters: Companies such as Orion Corporation (Finland, $3.32M) may import Fluoxetine for re-export to other markets, leveraging trade agreements and logistical advantages. Their buying behavior is influenced by global market demands and regulatory environments.
Country-Specific Import Regulations
TransData Nexus Fluoxetine buyer market intelligence
1Country-Specific Import Regulations
For the top five importing countries, the import regulations for Fluoxetine (HS Code: 30049099) are as follows:
1. United States
2. Canada
3. United Kingdom
4. Netherlands
5. South Africa
Demand Drivers & Market Opportunity
TransData Nexus Fluoxetine buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Fluoxetine in importing countries is driven by several factors:
1. Disease Prevalence: Fluoxetine is primarily used to treat major depressive disorder, anxiety disorders, and certain eating disorders. According to the World Health Organization (WHO), depression affects over 264 million people globally as of 2020, indicating a substantial patient base for Fluoxetine.
2. Government Healthcare Programs: Many countries have national healthcare programs that subsidize or cover the cost of essential medicines, including Fluoxetine. For instance, the UK's National Health Service (NHS) provides Fluoxetine as part of its formulary, ensuring widespread access.
3. Universal Health Coverage Expansion: Countries expanding their universal health coverage, such as South Africa's National Health Insurance (NHI) initiative, are increasing access to essential medicines, thereby boosting demand for Fluoxetine.
4. WHO Essential Medicines List Procurement: Fluoxetine is listed on the WHO Model List of Essential Medicines, prompting many countries to include it in their national essential medicines lists and procurement programs.
5. Tender-Based Purchasing: Government and international organizations often procure medicines through tenders to ensure cost-effectiveness and supply security. The presence of 522 buyers across 101 countries, as per TransData Nexus data, indicates a competitive market where tender-based purchasing is prevalent.
These factors collectively contribute to the sustained and growing demand for Fluoxetine in the global market.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Buyer Identification: 522 global importers of Fluoxetine identified from consignee fields in DGFT shipping bill records.
- 2.Import Value Analysis: Total import value aggregated from 3,702 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Geographic Distribution: Buyer imports distributed across 101 destination countries with market share per buyer calculated from capped values.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,702 Verified Shipments
522 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists